17 studies found for:    Study of MK-3475
Show Display Options
Rank Status Study
1 Recruiting Study of MK-3475 in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Condition: Solid Tumor
Intervention: Biological: MK-3475
2 Active, not recruiting Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)
Condition: Malignant Melanoma
Interventions: Drug: MK-3475;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Dacarbazine;   Drug: Temozolomide
3 Recruiting Study of MK-3475 in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
Conditions: Cancer;   Solid Tumor
Intervention: Drug: MK-3475
4 Recruiting Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Conditions: MSI Positive Colorectal Cancer;   MSI Negative Colorectal Cancer;   MSI Positive Non-Colorectal Cancers
Intervention: Drug: MK-3475
5 Recruiting Study of MK-3475 in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
Condition: Non-small Cell Lung Cancer
Intervention: Biological: MK-3475
6 Recruiting Study of MK-3475 Monotherapy in Participants With Advanced Solid Tumors and MK-3475 Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
Conditions: Solid Tumor;   Non-small Cell Lung Cancer
Interventions: Drug: MK-3475;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel
7 Recruiting A Study of MK-3475 in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Condition: Non-small Cell Lung Carcinoma
Interventions: Drug: MK-3475;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Pemetrexed;   Biological: Ipilimumab;   Drug: Erlotinib;   Drug: Gefitinib
8 Recruiting Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
Condition: Cancer, Solid Tumor
Interventions: Drug: MK-3475 1 mg/kg;   Drug: MK-3475 3 mg/kg;   Drug: MK-3475 10 mg/kg;   Drug: MK-3475 MEL;   Drug: MK-3475 NSCLC;   Drug: MK-3475 MEL Low Dose;   Drug: MK-3475 MEL High Dose;   Drug: MK-3475 NSCLC Low Dose;   Drug: MK-3475 NSCLC High Dose;   Drug: MK-3475 NSCLC Medium Dose
9 Recruiting A Study of MK-3475 in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
Condition: Multiple Myeloma
Interventions: Biological: MK-3475;   Drug: Lenalidomide;   Drug: Dexamethasone
10 Recruiting MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Conditions: Melanoma;   Non-Small Cell Lung Cancer;   Brain Metastases
Intervention: Drug: MK-3475
11 Recruiting Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Drug: MK-3475
12 Active, not recruiting Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Condition: Melanoma
Interventions: Drug: MK-3475;   Drug: Ipilimumab
13 Recruiting Study of Two Doses of MK-3475 Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Biological: MK-3475;   Drug: Docetaxel
14 Recruiting Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b and MK-3475 + Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029)
Conditions: Renal Cell Carcinoma;   Melanoma
Interventions: Biological: MK-3475;   Biological: PegIFN-2b;   Biological: Ipilimumab
15 Not yet recruiting Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Condition: Melanoma
Interventions: Drug: MK-3475;   Drug: Peginterferon alfa-2b
16 Recruiting A Trial of MK-3475 in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)
Conditions: Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Biological: MK-3475
17 Available Program for MK-3475 in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
Condition: Melanoma
Intervention: Biological: MK-3475

Indicates status has not been verified in more than two years